Jaguar Health
JAGX
0 hedge funds and large institutions have $873K invested in Jaguar Health in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
725% more call options, than puts
Call options by funds: $66K | Put options by funds: $8K
0% less ownership
Funds ownership: 0% → 0% (-0%)
50% less capital invested
Capital invested by funds: $1.74M → $873K (-$864K)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$916K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$11K |
| 3 |
Goldman Sachs
New York
|
-$3K |
JAGX Hedge Fund Activity: Q3 2022 in Review
0 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Jaguar Health (JAGX) for Q3 2022, worth a combined $873K — down 50% from $1.74M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of JAGX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $916K sold.
- 0 institutional investors held Jaguar Health (JAGX) as of Q3 2022, down from 1 in Q2 2022.
- Funds reported $873K of Jaguar Health stock for Q3 2022, down 50% quarter-over-quarter.
- 0 funds opened new Jaguar Health positions in Q3 2022 and 1 closed out, a net change of -1 holder.
- The largest Jaguar Health seller in Q3 2022 was Vanguard Group, an estimated $916K sold.
Based on aggregated 13F filings for Q3 2022.